Engineering Health: The Digital Transformation of Life Sciences

A Decisive Turning Point

Life sciences are entering a new era where AI, cloud, IoT, digital twins, and cybersecurity technologies are no longer options, but essential levers for optimizing R&D efficiency, ensuring regulatory compliance, accelerating time-to-market, and enhancing patient safety. This evolution is all the more critical as clinical trials and real-world evidence (RWE) studies become increasingly digital and gain momentum.

The Drivers of This Transformation

• AI-Augmented R&D: generative models can reduce early-stage drug development costs by up to 20% (McKinsey, 2024).
• Digital Twins: they simulate clinical processes and laboratory environments, improving trial design and production forecasting (MIT Technology Review, 2024).
• IoT Devices and Remote Monitoring: now standard in medtech, they require integrated cybersecurity to ensure data integrity and compliance (2025 FDA guidelines).
• Regulatory Complexity: regions such as the EU, the US, and Japan require robust systems to ensure traceability, auditability, and data quality (PwC, 2023).

Our Solution: ALSINOVA CRO, an Astek Group Company

Launched this summer, ALSINOVA is a CRO (Contract Research Organization) that combines decades of industry expertise with the power of AI, data science, and large-scale engineering.

Key Figures:

• Born from the acquisitions of Keyrus LS, Sanoïa, and IT&M Stats, along with the AI DNA of Simelabs.
• Over 500 experts across 26 countries, covering non-clinical and clinical phases as well as real-world evidence (RWE).
• An integrated offering combining clinical operations, data science, regulatory affairs, vigilance, and medical affairs, supported by digital solutions.

What Does This Mean in Practice?

ALSINOVA teams now offer end-to-end digital solutions:

• AI-Driven Data Analytics and Trial Design to accelerate study setup and insight generation.
• Digital Twins of clinical workflows and laboratories to optimize protocols, anticipate resource needs, and ensure traceability with a medical-grade approach.
• Connected IoT Devices for electronic data capture (EDC) and decentralized clinical trials (DCTs), secured by embedded encryption and compliance frameworks.
• Integrated Regulatory and Pharmacovigilance Platforms, powered by AI and deployed on scalable cloud/edge infrastructures.

This capability enables clients to conduct clinical programs that are faster, smarter, and more resilient.

Challenges and ALSINOVA’s Solutions

While technology opens new horizons, it also increases complexity:

• Regulatory Burden: ALSINOVA teams integrate global compliance (FDA, EMA, MDR) from the design phase throughout the entire study conduct.
• Data Security: combined IT/OT security, encryption, and audit capabilities to protect sensitive health data.
• Scalability vs. Agility: modular and scalable delivery models for a seamless transition from pilot projects to global deployment.

Key Takeaways

• The digital CRO is the new frontier of clinical research, combining data intelligence, speed of execution, and compliance.
• AI, digital twins, IoT, and secure cloud systems have now become industrialized practices within the life sciences sector.
• ALSINOVA positions Astek as a strategic player at the intersection of engineering, digital technology, and clinical services.